GlobeNewswire Inc.··NaZenas BioPharma Raises $300M Through Convertible Notes and Stock Offering
Zenas BioPharma prices $300M offering combining $200M convertible notes and 5M common shares to fund obexelimab launch and pipeline advancement.
ZBIOautoimmune diseasesequity offering